{
  "docId": "019de077-0ff3-70e8-97e9-f8df18ead978",
  "docSlug": "2f90f1dc6d9440d196c6f2643a698403",
  "documentTitle": "OmniAb | Results Presentation Deck | 24 slides",
  "authorId": "omniab",
  "authorName": "OmniAb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 24,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide highlights the company's pipeline growth and provides specific examples of partner programs.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-0ff3-70e8-97e9-f8df18ead978/9",
  "deckHref": "/decks/019de077-0ff3-70e8-97e9-f8df18ead978",
  "deckJsonHref": "/decks/019de077-0ff3-70e8-97e9-f8df18ead978.json",
  "deckAnchorHref": "/decks/019de077-0ff3-70e8-97e9-f8df18ead978#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.29,
        "x": 0.05,
        "y": 0.185
      },
      "kind": "chart",
      "text": "Number of Active Clinical Programs and Approved Products",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59b54db0-6dcb-4257-a5f9-fdab96ef625b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.6,
        "x": 0.34,
        "y": 0.25
      },
      "kind": "list",
      "text": "1. SGN-BB228 (Seagen): Anti-CD228 x 4-1BB Anticalin(1)\n2. IMVT-1402 (Immunovant): Next-generation FcRn antagonist\n3. GLS-012 (Gloria): Anti-LAG-3(2)\n4. RO7515629 (Roche): HLA-G x CD3(3)\n5. CSX-1004 (Cessation): Anti-fentanyl\n6. BC3195 (BioCity Biopharma): Anti-CDH3(2)",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "de9e460e-07ba-441a-aad4-b611e201f808",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.34,
        "y": 0.65
      },
      "kind": "paragraph",
      "text": "Based on dialog with partners, we see potential for approximately 4 - 6 new entries into clinical development for novel OmniAb-derived antibodies in 2024, with programs addressing major unmet medical needs",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "28da34e5-8a4c-4f8b-958f-13e668e055aa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.75,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "(1) Program is now referred to as PF-08046049 at Pfizer, following Pfizer's acquisition of Seagen which was completed in December of 2023.\n(2) Gloria and BioCity Biopharma programs do not have milestone payments associated with them, as a result of a payment in 2018 to buy out remaining milestones.\n(3) Roche program subject of a pre-paid license, per a 2013 agreement with OMT, Inc.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1476c31b-68b3-4bc4-aa6c-7e0fa684c044",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.65,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Programs are Advancing into the Clinic",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92a728a1-445f-4d20-975c-62f7f395b36d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 6,
      "beatId": "2e17e5b3-d484-44e3-9c23-8f5b421ab4ab",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The presentation showcases the company's progress and advancements",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 4,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "3d5a1a82-3964-408b-9b7e-ec01e0958d5f",
      "evidence": "The presentation outlines the company's strategy and progress",
      "position": 1,
      "objective": "Presenting a clear plan for growth",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}